On­col­o­gy spe­cial­ist Volas­tra brings in PhI drug from Am­gen, nabs $60M in Se­ries A

Al­most a year af­ter ink­ing a bil­lion-dol­lar biobucks deal with Bris­tol My­ers Squibb, NYC biotech Volas­tra Ther­a­peu­tics is link­ing up with two oth­er phar­ma gi­ants in a one-two com­bo — in­volv­ing an in-li­cens­ing and some cash from well-known in­vestors to keep its work mov­ing.

Volas­tra put out word Tues­day morn­ing that it has fin­ished in-li­cens­ing so­vil­ne­sib from Am­gen. So­vil­ne­sib, al­so known as AMG 650, is an oral in­hibitor of KIF18A, one of the tar­gets that Volas­tra has fo­cused on in its pur­suit of chro­mo­so­mal in­sta­bil­i­ty. The deal gives Volas­tra an ex­clu­sive li­cense to de­vel­op and com­mer­cial­ize the drug any­where world­wide ex­cept for Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER